2'-甲基-2'-脱氧亚基胞苷 | 119804-96-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2'-甲基-2'-脱氧亚基胞苷
• 英文名称: 2'-deoxy-2'-methylenecytidine
• 英文别名: 1-(2-deoxy-2-methylene-β-D-erythro-pentofuranosyl)cytosine；2’-deoxy-2’-methylidenecytidine；2'-deoxy-2'-methylidenecytidine；2'-deoxy-2'-methylinecytidine；DMDC；2'-deoxy-2'-methylidene-cytidine；4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-3-methylideneoxolan-2-yl]pyrimidin-2-one
• CAS: 119804-96-5
• 化学式: C₁₀H₁₃N₃O₄
• 分子量: 239.231
• InChiKey: PULHLIOPJXPGJN-BWVDBABLSA-N

物化性质

• 熔点：
  190-194 °C (decomp)(Solv: water (7732-18-5))
• 沸点：
  494.8±55.0 °C(Predicted)
• 密度：
  1.63±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2'-甲基-2'-脱氧亚基胞苷 在 phospholipase A2 、 sodium salt of choleic acid 、 sodium acetate buffer 、 3,3-dimethylglutarate-NaOH buffer 、 Dianion WK-20 resin (Na⁽¹⁺⁾ form) 、 calcium chloride 、 phospholipase D 作用下， 反应 6.0h， 生成
  参考文献：
  名称：

  Nucleosides and nucleotides. 155. synthesis, antitumor effects, and possible enzymatic activation mechanism of 5′-phosphatidyl-2′-deoxy-2′-methylenecytidine (DMDC)

  摘要：

  2'-Deoxy-2'-methylenecytidine (DMDC, 1) and its 5-fluoro congener (5-F-DMDC, 2), potent antitumor nucleosides developed by us, were efficiently converted to their 5'-phosphatidyl derivatives bearing palmitoyl residues (3 and 4, respectively) as novel antitumor phospholipids by phospholipase D-catalyzed trans-phosphatidylation. These phospholipids 3 and 4, administered i.p., remarkably prolonged the life-span of mice which were i.p.-inoculated with M5076 sarcoma, and the effects were clearly superior to that of DMDC. Compound 3 was a good substrate for phospholipase A(2) from bovine pancreas as well as phospholipase D from Streptomyces, while it was slightly hydrolyzed by phospholipase C from Bacillus cereus. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00389-7
• 作为产物：
  描述：

  N⁴-benzoyl-1-[2-deoxy-2-methylidene-3,5-di-O-benzoyl-β-D-glycero-pentofuranosyl]cytosine 在 氨 作用下， 以 甲醇 为溶剂， 生成 2'-甲基-2'-脱氧亚基胞苷
  参考文献：
  名称：

  2'-脱氧-2'-氟-2'-C-甲基胞苷（一种有效的丙型肝炎病毒复制抑制剂）的设计，合成和抗病毒活性。

  摘要：

  嘧啶核苷β-d-2'-脱氧-2'-氟-2'-C-甲基胞嘧啶核苷（1）被设计为丙型肝炎病毒RNA依赖性RNA聚合酶（HCV RdRp）抑制剂。通过DAST氟化N（4）-苯甲酰基-1-（2-甲基-3,5-二-O-苯甲酰基-β-d-阿拉伯呋喃糖基]胞嘧啶，得到N（4）-苯甲酰基-标题化合物，得到标题化合物。 1- [2-氟-2-甲基-3,5-二-O-苯甲酰基-β-d-呋喃呋喃糖基]胞嘧啶，从DAST氟化得到的副产物为2'-C-甲基胞嘧啶核苷，并用于由共同的前体制备两种具有生物活性的化合物，在亚基因组HCV复制子检测系统中测定了化合物1和2'-C-甲基胞嘧啶核苷，发现它们是有效且选择性的HCV复制抑制剂，化合物1在HCV中显示出更高的抑制活性复制子测定与2'相比

  DOI：

  10.1021/jm0502788

文献信息

• [EN] ERK INHIBITORS<br/>[FR] INHIBITEURS D'ERK
  申请人：MERCK SHARP & DOHME

  公开号：WO2016100050A1

  公开（公告）日：2016-06-23

  The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.

  本发明提供了一种化合物(I)或其药学上可接受的盐、酯和前药，这些化合物是ERK2抑制剂。该发明还提供了一种包括至少一种化合物(I)和药学上可接受的载体的有效量的药物组合物。该发明还提供了一种包括至少一种化合物(I)的有效量和至少一种其他药学活性成分的有效量（例如，化疗药物等）以及药学上可接受的载体的药物组合物。
• [EN] TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE<br/>[FR] INHIBITEURS TRICYCLIQUES DE POLY(ADP-RIBOSE)POLYMÉRASE
  申请人：NEWGEN THERAPEUTICS INC

  公开号：WO2012166983A1

  公开（公告）日：2012-12-06

  The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-l(2H)-one derivatives. The compounds are potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular activity in inhibiting poly(ADP- ribose) oligomer formation. The compounds may be useful as mono-therapy or in combination with other therapeutic agents in the treatment conditions where PARP is implicated, such as cancer, inflammatory diseases and ischemic conditions. Thus, also provided are methods for the treatment of a condition where PARP is implicated comprising administering to an effective amount of a compound of the invention to an individual in need thereof.

  该发明提供了包含含磷三环化合物的组合物，包括邻苯二氮杂吲哚酮衍生物。这些化合物是酶聚(腺苷二磷酸核糖)聚合酶（PARP）的有效抑制剂，特别是PARP-1和潜在的PARP-2。它们还显示出在抑制聚(腺苷二磷酸核糖)寡聚物形成方面具有良好的细胞活性。这些化合物可能在单独治疗或与其他治疗剂联合治疗PARP参与的疾病条件中发挥作用，如癌症、炎症性疾病和缺血性疾病。因此，还提供了一种治疗PARP参与的疾病条件的方法，包括向需要的个体施用该发明化合物的有效量。
• Spirocyclic compounds
  申请人：Berk C. Scott

  公开号：US20070117824A1

  公开（公告）日：2007-05-24

  The present invention relates to a novel class of substituted spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.

  本发明涉及一类新型的取代螺环化合物。这些化合物可以抑制组蛋白去乙酰化酶，并适用于在选择性诱导终末分化、阻止肿瘤细胞生长和/或凋亡的过程中使用，从而抑制这些细胞的增殖。因此，本发明的化合物在治疗具有肿瘤特征的患者方面是有用的，这些肿瘤具有肿瘤细胞的增殖。本发明的化合物还可能在预防和治疗TRX介导的疾病方面有用，例如自身免疫、过敏和炎症性疾病，以及预防和/或治疗中枢神经系统（CNS）疾病，如神经退行性疾病。本发明还提供了包括本发明化合物的药物组合物和这些药物组合物的安全用药方案，这些方案易于遵循，并在体内产生这些化合物的治疗有效量。
• [EN] MITOTIC KINESIN INHIBITORS<br/>[FR] INHIBITEUR DE KINESINES MITOTIQUES
  申请人：MERCK & CO INC

  公开号：WO2003105855A1

  公开（公告）日：2003-12-24

  The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

  本发明涉及对二氢吡咯烷化合物，其用于治疗细胞增殖性疾病，治疗与KSP动力蛋白活性相关的疾病，以及抑制KSP动力蛋白。该发明还涉及包含这些化合物的组合物，以及使用它们治疗哺乳动物癌症的方法。
• Active salt forms with tyrosine kinase activity
  申请人：——

  公开号：US20040023978A1

  公开（公告）日：2004-02-05

  The present invention relates to orally active salt forms of the mesylate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.

  本发明涉及口服活性盐形式的甲磺酸盐，其抑制、调节和/或调控酪氨酸激酶信号传导的4-[2-(5-氰基噻唑-2-基氨基)-吡啶-4-基甲基]-哌嗪-1-羧酸甲酰胺，含有这些化合物的组合物，以及使用它们治疗酪氨酸激酶依赖性疾病和症状的方法，如血管生成、癌症、肿瘤生长、动脉粥样硬化、老年性黄斑变性、糖尿病视网膜病变、视网膜缺血、黄斑水肿、炎症性疾病等哺乳动物。